SCHEMBL2806925

SCHEMBL2806925

Fc1ccc(CCNc2ncc3c(n2)CCc2cnc4[nH]ncc4c2-3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.39
SLC29A1 Q99808 1/20 0.37
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
PRKCQ Q04759 1/20 0.35
HTR2A P28223 4/20 0.35
HTR2C P28335 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
IP6K1 Q92551 1/20 0.35
HTR7 P34969 1/20 0.34
HRH1 P35367 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
ULK1 O75385 1/20 0.34
PLK4 O00444 1/20 0.34
PAK4 O96013 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804807 0.84 SLC29A1 (0.42) RPS6KB1SLC29A1CCNA2CDK2PRKCQ
SCHEMBL2802889 0.83 RPS6KB1 (0.43) RPS6KB1SLC29A1CCNA2CDK2HTR2C
SCHEMBL2805133 0.81 RPS6KB1 (0.52) RPS6KB1PRKCQHTR2AHTR2CPLK4
SCHEMBL2803843 0.81 CCNA2 (0.42) RPS6KB1CCNA2CDK2LMNAPOLB
SCHEMBL2802228 0.79 AKT1 (0.38) RPS6KB1CCNA2CDK2LMNAMAPT
SCHEMBL2804059 0.78 DYRK1A (0.48) RPS6KB1
SCHEMBL2806420 0.78 CDK2 (0.39) RPS6KB1SLC29A1CCNA2CDK2MAPT
SCHEMBL2805205 0.78 CCNA2 (0.45) CCNA2CDK2HTR2A
SCHEMBL2802884 0.77 CDK2 (0.47) CCNA2CDK2
SCHEMBL2805136 0.76 LCK (0.41) RPS6KB1CCNA2CDK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 RPS6KB1 1992/4885SLC29A1 1627/4885CCNA2 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.